Rethinking phase III trials in retinal biosimilars: Do we still need them?

Eye (Lond). 2026 Apr 22. doi: 10.1038/s41433-026-04480-7. Online ahead of print. NO ABSTRACT PMID: 42020545 | DOI: 10.1038/s41433-026-04480-7